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Abstract Cerebrovascular reactivity is the change in cerebral blood flow in response to a vaso-
dilatory or vasoconstrictive stimulus. Measuring variations of cerebrovascular reactivity between
different regions of the brain has the potential to not only advance understanding of how the
cerebral vasculature controls the distribution of blood flow but also to detect cerebrovascular
pathophysiology.While there are standardized and repeatablemethods for estimating the changes
in cerebral bloodflow in response to a vasoactive stimulus, the same cannot be said for the stimulus
itself. Indeed, thewidevarietyof vasoactive challenges currently employed in these studies impedes
comparisons between them. This review therefore critically examines the vasoactive stimuli in
current use for their ability to provide a standard repeatable challenge and for the practicality of
their implementation. Such challenges include induced reductions in systemic blood pressure,
and the administration of vasoactive substances such as acetazolamide and carbon dioxide. We
conclude that many of the stimuli in current use do not provide a standard stimulus comparable
between individuals and in the same individual over time. We suggest that carbon dioxide is
the most suitable vasoactive stimulus. We describe recently developed computer-controlled MRI
compatible gas delivery systems which are capable of administering reliable and repeatable vaso-
active CO2 stimuli.
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Introduction
Cerebral bloodflow (CBF) is carefully regulated to provide
nutrients and oxygen to the various regions of the brain.
Metabolic coupling mechanisms ensure that blood flow is
increased in active regions (Iadecola & Nedergaard, 2007;
Attwell et al. 2011; Paulson et al. 2011), and autoregulation
ensures that bloodflow ismaintained in the face of changes
in perfusion pressure (Lucas et al. 2010). The cerebral
vasculature also responds to carbon dioxide and hypoxia
(Kety & Schmidt, 1948; Mardimae et al. 2012). The action
of these various factors serves to control the distribution
of cerebral blood flow. One of the ways investigators
have probed the regulation of cerebral blood flow and its
distribution is to challenge the system with a vasoactive
stimulus and observe the response. Such experiments
measure the cerebrovascular reactivity (CVR), the change
in CBF per change in vasoactive stimulus.
For example, recent studies using trans-cranial Doppler
(TCD) measurements of CBF and carbon dioxide (CO2)
as a vasoactive stimulus have found differences in CVR
between themajor cerebral arteries (Sato et al. 2012;Willie
et al. 2012). And, as Fig. 1 shows, maps of CVR obtained
from blood oxygen level-dependent (BOLD) magnetic
resonance imaging (MRI), which is used as a surrogate
for cerebral blood flow, can detect inhomogeneities in
the distribution of cerebral blood flow. The BOLD
signal is degraded in proportion to the concentration of
deoxyhaemoglobin in a voxel. It represents the net balance
between O2 delivery and O2 consumption. At physio-
logical levels of tissue blood flows, the BOLD signal and
Figure 1. Example CVR maps
CVR is the ratio of the change in the BOLD-MRI signal in response to
a change in CO2 stimulus, and is colour coded voxel by voxel
according to the scale provided in the colour bar, and superimposed
on the corresponding voxel of the anatomical scan. A, CVR map
measured in a healthy volunteer. B, CVR map measured in a patient
with moya moya disease. Although the hypercapnic stimulus was
the same in each subject, the distribution of the changes in blood
flow in the patient with moya moya disease revealed multiple areas
of reduced cerebrovascular reactivity in response to the global
vasodilatory stimulus. These regions of reduced CVR are the result of
vascular steal, where stimulus-induced reductions in flow resistance
result in flow diversion from regions of low to high vasodilatory
reactivity.
blood flow approximate a linear relationship (assuming
O2 consumption is constant). Measuring variations of
cerebrovascular reactivity between different regions of
the brain has the potential to not only advance under-
standing of how the cerebral vasculature controls blood
flow and its distribution but also to detect cerebrovascular
pathophysiology (e.g. Mandell et al. 2011).
However, currently published CVR studies use different
combinations of vasoactive stimuli and measures of
CBF, generating results that are difficult to compare.
Although the methods of measuring CBF differ in their
sensitivity, specificity, and spatial and temporal resolution,
each does, nevertheless, generate highly repeatable and
specific measures (see Wintermark et al. 2005 for review).
The same cannot be said of the vasoactive stimulus.
The many vasoactive stimuli that have been used to
increase CBF generate results that are difficult to compare
between studies. Even within a single method, the vaso-
dilatory effect is seldom uniform, repeatable, or even
quantifiable. It is this inability to standardize the vaso-
active stimulus, or alternatively, precisely and accurately
measure the stimulus at the active site, that has most
impeded comparison of CVR between various studies,
and between individuals in the same study.
We therefore set out to survey vasoactive stimuli used to
generate CVRmeasures.We conclude that CO2 is themost
appropriate stimulus in terms of its practicality of use and
ability to be standardized. Since CBF responds to arterial
CO2 tension, we reviewmethods of controlling the arterial
partial pressure of CO2 (Pa,CO2), specifically commenting
on their anticipated advantages and limitations used for
making CVR measurements. We then present a detailed
description of an automated prospective method of
targeting Pa,CO2 developed in our laboratory. We note
that the various methodologies for controlling Pa,CO2
are complex and require some knowledge of respiratory
physiology in order to appreciate the subtleties involved.
Accordingly, we provide an Appendix containing a brief
glossary and summaryof thebasic principles of respiratory
physiology pertinent to the control of CO2 as a vasoactive
stimulus.
Vasodilatory challenges
The main types of vasoactive stimuli. To measure CVR,
three types of vasodilatory challenges have been utilized:
(1) the applicationof a transient reduction inmeanarterial
blood pressure (MacKenzie et al. 1979), (2) the injection
of an exogenous chemical (e.g. acetazolamide; Vorstrup
et al. 1986) and (3) an increase in Pa,CO2 (e.g. Poulin et al.
1996). The ease of use of each method as a standardized
stimulus is assessed in the following sections.
Systemic blood pressure as a stimulus. At first glance,
a reduction in systemic blood pressure (Panerai, 1998)
C© 2013 The Authors. The Journal of Physiology C© 2013 The Physiological Society
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appears to be the ideal vasodilatory challenge for
testing the basic autoregulatory response of the cerebral
vasculature. However, the induction of a safe, titratable
and repeatable hypotensive stimulus is challenging.
Inducing hypotension by administering vasodilators
makes it difficult to separate the vascular effects resulting
from autoregulation and those resulting from the direct
effect of vasodilators (Artru & Colley, 1984) Abrupt
thigh cuff release (single step change in blood pressure;
Aaslid et al. 1989) and lower body negative pressure
(cyclic changes in blood pressure; Tan, 2012) are designed
to examine dynamic cerebral autoregulation. Tan et al.
(2012), for example, examine the loss of coherence
between arterial pressure changes and TCD signal changes
as an index of autoregulation. However, these methods
reduce blood pressure through a reduction in venous
return and effectively central blood volume. The extent
of the ensuing hypotension in healthy subjects is variable
(Mahony et al. 2000), and is expected to be more variable
if performed in patients over a range of ages, with
multiple underlying co-morbidities and taking an array
of medication. Hypotensive provocation would also be
a concern for patients at risk of hypotension-induced
ischaemia such as those with already haemodynamically
precarious regional brain blood flow (Symon, 1969;
Mandell et al. 2008).
Hypotension vs. chemical stressors. These considerations
regarding hypotension have resulted in a preference
for the administration of chemical cerebral vasodilators
to test vasodilatory reserve in clinical studies. To do
so, investigators had to address the concern that the
mechanism of vasodilatation due to autoregulation may
not be the same as for a chemical stimulus such as
acetazolamide (ACZ) or CO2 (Lundar et al. 1985) The
conclusion of studies performed over the last half-century
is that regardless of the underlying mechanisms,
cerebrovasodilators and pressure autoregulation draw on
the same vasodilatory reserve (Symon, 1968; Nishimura
et al. 1999). Reductions in perfusion pressure, resulting
in autoregulatory vasodilatation, progressively dampen
both the vasoconstrictor (Artru & Colley, 1984) and vaso-
dilatory responses to CO2 in dogs (Harper, 1965) and
humans (Vorstrup et al. 1986; Ringelstein et al. 1992;
Nishimura et al. 1999). Overall, these studies indicate
that chemical stimuli, and in particular hypercapnia, are
suitable for interrogating the brain vasculature for regions
with limited vasodilatory capacity.
Exogenous chemical acetazolamide as a stimulus. In
1986, Vorstrup et al. (1986) introduced the use of intra-
venous administration of 1 g of the carbonic anhydrase
inhibitor ACZ as a maximal vasodilatory stimulus for
measuring CVR. Indeed, ACZ continues to be the most
widely applied stimulus for cerebral vasodilatation in
a clinical setting and is used with TCD (Ringelstein
et al. 1992; Gur et al. 1996), 133Xe enhanced-CT
(Yonas et al. 1993), single positron emission computed
tomography (SPECT), (Hasegawa & Yamaguchi, 1993;
Kuroda et al. 2001) and BOLD MRI (Asghar et al.
2011). ACZ administration produces an extracellular
and intracellular acidosis resulting in the relaxation of
vascular smooth muscle. The advantages claimed for ACZ
as a cerebral vasodilator are the simplicity of a single
dose injection (Okazawa et al. 2001), its reproducibility
independent of subject cooperation, and its high safety
profile.
However, a standardized dose of ACZ does not generate
the reproducible stimulus required for standardizing
CVR measurement. First, there is considerable individual
variability in the response to ACZ; both the serum ACZ
concentrations for a given dose, and the cerebrovascular
responses to a given serum level, vary between subjects.
These unpredictable and uncontrollable influences pre-
vent a reproducible stimulus–response relationship. It
has been suggested that the best way to standardize the
use of ACZ for CVR is to give a large enough dose to
obtain a maximal CBF response. However, this approach
also poses difficulties as there are large inter-subject
variations in ACZ’s time to peak effect, duration of
action, and elimination rate. While a single 1 g dose of
ACZ, is assumed to provide a supramaximal stimulus
(Ringelstein et al. 1992; Okazawa et al. 2001), this single
dose does not reliably produce a maximum CBF if it is
less than 15mg kg−1 (Dahl et al. 1995; Grossmann &
Koeberle, 2000). Evenwith an effective supramaximalACZ
dose, CBF continues to respond to ventilation-induced
changes in PCO2 and to changes in blood pressure
(Vorstrup et al. 1986); both are confounding factors
affecting CBF. Second, doses in the 15mg kg−1 range are
associated with a high incidence of side-effects, including
dizziness, nausea, vomiting, headache,malaise and neuro-
logical symptoms related to ischaemia (Dahl et al. 1995;
Grossmann & Koeberle, 2000). Even at lower doses there
are symptomatic complaints following ACZ in 40–60% of
subjects (Ringelstein et al. 1992; Saito et al. 2011). Amajor
disadvantage of ACZ is that in case of adverse events or
subject discomfort the effects are not easily terminated.
Altogether, these issues limit the desirability of ACZ as
a vasoactive stimulus. An alternative stimulus is needed.
On the basis that CVR measures using CO2 are similar to
those using ACZ, (Markus & Harrison, 1992; Ringelstein
et al. 1992; Gooskens et al. 2003), it is reasonable to
consider CO2 as a suitable candidate for the vasodilatory
stimulus.
Carbon dioxide as a stimulus. CO2 as a vasodilatory
stimulus has many advantages. Increases in Pa,CO2 raise
CBF by about 3% (Fortune et al. 1992) or more under
C© 2013 The Authors. The Journal of Physiology C© 2013 The Physiological Society
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hypoxic conditions (Poulin et al. 2002), and in contrast
to intravenously injected ACZ, the administration of CO2
is non-invasive and easily terminated. CBF closely follows
changes in Pa,CO2 for TCD measurements of the middle
cerebral artery flow velocity (Poulin et al. 1996), and even
faster for BOLD MRI measures as we show later. The
physiologicalmechanismsof vasodilatationwithCO2 have
been reviewed (Brian, 1998). Moderate hypercapnia with
end-tidal PCO2 (PET,CO2) controlled at tensions between
40 and 50mmHg is well tolerated by conscious humans
(Steinback et al. 2009; Spano et al. 2012). Furthermore,
CO2 administration is safe even in critically ill patients, and
evenwhen applied for prolonged periods (e.g. weeks; Feihl
& Perret, 1994; O’croinin et al. 2005). A further indication
of the safety of hypercapnia comes from case reports of
accidental extreme hypercapnia; patients have recovered
from Pa,CO2 values exceeding 200mmHg without adverse
neurological sequellae after nothingmore than restoration
of normal ventilation (Potkin & Swenson, 1992; Ayas et al.
1998).
Despite these advantages, few clinical studies have
considered using CO2 as the vasoactive stimulus and
its use is mostly in laboratory studies. One of the
reasons cited against using CO2 is that changing Pa,CO2
requires some type of ventilatory manoeuvre such
as breath-holding or voluntary hyperventilation, and
therefore some cooperation from the subject, as opposed
to ACZ, which can simply be injected intravenously.
Furthermore, the perception is that the extent of the
stimulus cannot be as easily regulated as drug dosing.
Indeed, this latter difficulty in controlling Pa,CO2 has been
an incentive to develop new technology for targeting and
maintaining Pa,CO2 tension.
Whether to use hypocapnia or hypercapnia is the first
consideration. Hypocapnia has a vasoconstrictive effect
on the brain vasculature, thereby reducing cerebral blood
flow (Raichle & Plum, 1972) and has been used for CVR
mapping (Bright et al. 2009). However, Ringelstein et al.
(1988, 1992) induced hypocapnia for clinical CVR testing
by hyperventilation in patients with an occlusion of the
internal carotid artery and found that, in comparison
with a hypercapnic stimulus and acetazolamide, hypo-
capnia led to a relatively blunted response of CVR.
Furthermore, a hypocapnic manoeuvre for CVR testing
in subjects with traumatic brain injury led to an even
more heterogeneous response (Steiner et al. 2005). It
also seems counterintuitive to reduce CBF by hyper-
ventilation for identifying patients at risk for cerebral
ischaemia. Therefore, a hypercapnic vasodilatory stimulus
is more often applied for clinical CVR examinations.
Before describing these new approaches for controlling
Pa,CO2 , we review specific methods employed in recently
published studies to produce hypercapnia. Please refer
to the Appendix for an explanation of the terms and
respiratory physiology involved.
Hypercapnia
Breath-holding. One of the earliest methods used
to induce hypercapnia was breath-holding to pre-
vent CO2 elimination, which results in a progressive
increase in Pa,CO2 with time. The use of breath-holding
for CVR measurement was first demonstrated by
Ratnatunga & Adiseshiah (1990), used clinically with
TCD measurements of blood velocity to assess the risk of
stroke in symptomatic patients with carotid artery disease
(Markus & Harrison, 1992; Kastrup et al. 1999, 2001;
Silvestrini et al. 1999, 2000; Vernieri et al. 1999). In these
studies, breath-holding time was taken as an indicator
of the strength of the vasoactive stimulus and used to
normalize the change in CBF signal for stimulus strength,
and establish a ‘breath hold index’ (Kastrup et al. 1999;
Silvestrini et al. 1999, 2000; Vernieri et al. 1999).
The problem with this approach is the tenuous
relationship between breath-holding time and the actual
Pa,CO2 stimulus controlling CBF: breath-holding time is
only one of several factors determining the actual change
in Pa,CO2 . Other factors include the metabolic rate of
the subject, the size of the lungs (which vary with age,
sex, height, abdominal girth, body position, extent of
chest compression with fat, presence of obstructive and
other lung diseases etc.), recent ventilation history (e.g.
if preceded by hyperventilation, the Pa,CO2 may change
little if at all), and whether the subject inspired or
expired immediately before breath-holding. Even if these
factors are somehow controlled, Pa,CO2 is still not a linear
function of breath-holding time as has been assumed
(Sasse et al. 1996; Stock et al. 2006). Finally, the duration of
breath-holding is highly variable between subjects, varying
by more than 4 times (see Table I of Markus & Harrison,
1992), even within the same subject (Totaro et al. 1999).
All of these factors contribute to a large variability and
non-linear relation between breath-holding times and
the resulting Pa,CO2 stimulus; an issue that cannot be
addressed if CVR measures are to be comparable. While
breath-holding techniques can be refined (Scouten &
Schwarzbauer, 2008;Murphy et al. 2011; Bright&Murphy,
2013), by including end-tidal measures for example, they
have not been shown to provide CVR maps that reliably
identify cerebrovascular pathology because the threshold
stimulus for all pathological conditions is still unknown.
These drawbacks make breath-holding unsuitable as a
methodof producing a standardizedhypercapnic stimulus
for CVR measurements.
Inspired CO2. A second commonly used method of
increasing Pa,CO2 is the administration of a fixed inspired
fractional concentration of CO2. Breathing 2, 5 or 7%
CO2 via a tight fitting non-rebreathing face mask is
often considered to produce a standard hypercapnic
stimulus (Bishop et al. 1987; Ringelstein et al. 1988, 1992;
Hoge et al. 1999; Vernieri et al. 2004). However, despite
C© 2013 The Authors. The Journal of Physiology C© 2013 The Physiological Society
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widespread confidence in this approach, a fixed inspired
fractional concentration of CO2 does not produce a fixed
related Pa,CO2 , but one that varies both between subjects
and within the same subject over time (Hoskins, 1990;
Prisman et al. 2008). Indeed, the resulting Pa,CO2 varies
with metabolic rate and ventilation; the latter depending
on the CO2 chemoreflex sensitivity of the individual
(Duffin, 2011). Such chemoreflex-mediated increases in
ventilation, responding to the CO2 in the inspired gas,
moderate the rise in Pa,CO2 . Subjects with high chemo-
reflex sensitivities have greater increases in ventilation and,
consequently, a lower Pa,CO2 stimulus for CVR (Ainslie &
Duffin, 2009). As a result, for inspired CO2 fractions of
5% or less, the CO2-mediated ventilatory response may
produce an unchanged, or even lowered Pa,CO2 (Baddeley
et al. 2000). Furthermore, any increased ventilation also
increases arterial PO2 (Pa,O2) even if the inspired PO2
remains constant (Floyd et al. 2003; Prisman et al. 2008;
Mark et al. 2010). For example, Wise et al. (2007) found a
15mmHg increase in PO2 when subjects breathed 5%CO2
in air. If BOLD MRI is used to measure CVR under these
conditions, this rise in Pa,O2 would result in a small but
measurable∼0.3% increase in the BOLD signal (Prisman
et al. 2008), which is about 10% of typical signal changes
seen with a 10mmHg increase in PCO2 .
To circumvent this problem it has been argued that,
regardless of the ventilatory response to administeredCO2,
end-tidal PCO2 (PET,CO2) is a suitable surrogate for Pa,CO2 ,
and therefore PET,CO2 can be used as the stimulus for CBF
(Hoskins, 1990; Ringelstein et al. 1992; Mark et al. 2011).
In young healthy people, the gradient between PET,CO2
and Pa,CO2 may indeed be small – on average – but it is
nevertheless unknown. The gradient between arterial and
end-tidal measurements (Robbins et al. 1990) varies in
an individual with age (Miller & Tenney, 1956; Badgwell
et al. 1987), exercise (Jones et al. 1979), body position
(Barr, 1963), and disease (Yamanaka & Sue, 1987; Liu
et al. 1995; Prause et al. 1997). Even the assumption of a
constant relation between PET,CO2 and Pa,CO2 may not be
correct. In patients with lung disease, changes in PET,CO2
and Pa,CO2 are concordant only about 70% of the time
(Russell & Graybeal, 1994; Grenier et al. 1999; McDonald
et al. 2002). Thus, providing a fixed known inspired CO2
fractional concentration andmeasuring thePET,CO2cannot
standardize thePa,CO2 stimulus, and is therefore unsuitable
for measuring CVR quantitatively.
Rebreathing. Rebreathing exhaled gas is a traditional
means of increasing PCO2 (Read, 1967). Its main
advantages are that no external source of CO2 is required
and the basic apparatus, consisting of an exhaled gas
reservoir and gas sensors are readily available. It lends
itself to testing CVR as there is equilibration between
arterial, and alveolar PCO2 , which can be measured with
each breath. The PET,CO2 , and hence the Pa,CO2 , can span a
range of values potentially enabling the exploration of the
dynamic relationship between Pa,CO2 and CBF.
However, there are a number of caveats which, if not
addressed, limit its usefulness. First, during rebreathing,
oxygen is continuously consumed from the reservoir
changing the PO2 , which should be kept constant for CVR
measurement. Second, Pa,CO2 values, and hence CBF are
changing continuously. This ramp stimulus is not suitable
for use with measures of CBF that drift over time such as
BOLD MRI, or that require steady states like arterial spin
labeling (ASL) (Hajjar et al. 2010); if CBF measures with
high time resolution are used, they must be matched to
the constantly changing Pa,CO2 . Third, the rate of rise of
PCO2 is difficult to predict or control; depending on the
individual’s rate of CO2 production and the size of the
rebreathing reservoir. Smaller reservoirs provide a more
rapid rise in PCO2 but may not provide adequate volume
reserve for the larger tidal volumes as PCO2 rises (Russo
et al. 2000), and larger reservoirs prolong the rise time
of PCO2 , confounding measures of CBF that drift over
time. Finally, contrary to the assertion that rebreathing
quickly leads to a detectable ‘steady state plateau’ (Russo
et al. 2000; Glodzik et al. 2011; Lee & Lee, 2011), complete
rebreathing does not result in a plateau of PCO2 as long
the subject is alive (and producing CO2). Plateaus are only
reached with incomplete rebreathing, such as the addition
of a dead space (Glodzik et al. 2011) or as a result of holes
in the rebreathing bag (Lee & Lee, 2011). Moreover, such
plateau PCO2 values are not predictable (SD in one study
was 3.5 mmHg; Lee & Lee, 2011), and the time constants
for reaching actual plateaus in these cases are typically very
long, and seldom attained (see Fig. 1 in Lee & Lee, 2011).
From these considerations it is apparent that
rebreathing requires modification before it can be used
to provide a stimulus for CVR measurement. Indeed,
using rebreathing to measure the distribution of cerebral
blood flow using BOLD MRI imaging is not appropriate;
methodsofmaintaining a constantPO2 , and compensating
for its effect on BOLD signal have not been developed.
However, a specialized rebreathing method where iso-
xia is maintained during rebreathing has been developed
for measuring the characteristics of the respiratory
chemoreflexes (Duffin, 2011) and is suitable for CVR
measurements using TCD. Originally modified from the
rebreathing method proposed by (Read, 1967) and first
described by (Casey et al. 1987), the isoxic rebreathing
method has been extensively reviewed (Jensen et al.
2010; Duffin, 2011). In this method, PET,CO2 and Pa,CO2
are equivalent, satisfying the requirements for a known
measured hypercapnic stimulus, with end-tidal PO2
(PET,O2) maintained constant. Recently this method has
been adopted for use with TCD to measure blood flow
velocity in a number of studies (e.g. Fan et al. 2010; Skow
et al. 2013) and to describe the sigmoidal response to CO2
(Claassen et al. 2007; Battisti-Charbonney et al. 2011).
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Dynamic end-tidal forcing. The first computerized
method to control PET,CO2 and PET,O2 was developed
by Swanson & Bellville (1975) and termed dynamic
end-tidal forcing (DEF). It is implemented using a
computer-controlled gas blender (Robbins et al. 1982b)
with a feedback algorithm(Robbins et al. 1982a) to control
the inspired concentration of source gases O2, CO2 and
N2, to target PET,CO2 and PET,O2 . To produce a sequence
of changes in PET,CO2 and PET,O2 a predictive algorithm is
used to calculate the inspired gas fractional concentrations
necessary to produce the target end-tidal tensions. DEF
has been used to control PET,CO2 and PET,O2 during BOLD
MRI imaging for CVR in a single study of four subjects
(Wise et al. 2007) and of coronary vascular reactivity in 15
subjects (Beaudin et al. 2011).
In operation, the difference between the target and
actual end-tidal tensions is assessed on a breath-by-breath
basis, and using the known inspired concentrations of
gases, the errors in the inspired concentrations can be
determined.With that error information and a prediction
of the size of the next breath, the system controller
calculates the corrections to the programmed inspired
gas concentrations necessary to attain the target end-tidal
tensions in the next breath. These corrective actions are
made continuously when steady target end-tidal tensions
are required. However, for rapid changes, the controller
shortens the time for transition by overcompensating, and
then reverts to maintaining corrective actions. For rapid
decreases in PET,CO2 the method depends on increased
ventilatory drive or voluntary hyperventilation.
While the DEF system is capable of controlling
end-tidal gasses, we suggest that it is not suitable for
clinical CVR testing for a number of reasons. First,
implementation of theDEF systemposes somedifficulties.
It is resource intensive, requiring an extensive and complex
infrastructure (see Fig. 1 of Wise et al. 2007) because
the system requires high flows (∼70 l min−1) in order to
exceed the subject’s peak inspiratory flow, which must be
humidified before delivery to an open cone fromwhich the
subject breathes. The installation must therefore include
themeans to store and supply large volumes of humidified
gas at high flows via large diameter tubing, and a breathing
circuit with MRI-compatible electronic components such
as flow sensors. Second, its performance in terms of
accuracy and speed need improvement. Step increases in
PET,CO2 are slow; despite utilizing ‘overpressure’ the time
to transition to a new PET,CO2 can takemore than aminute
(Beaudin et al. 2011). And for maintaining steady target
tensions, the DEF control system prediction-correction
algorithm has inherent breath-to-breath variations in
PET,CO2 and PET,O2 of up to 2mmHg (see Fig. 2, panel 2, in
Wise et al. (2007) and Fig. 1 in Beaudin et al. (2011)).
Third, as previously discussed, the relation between
PET,CO2 (the measured value) and Pa,CO2 (the actual CVR
stimulus) is not known in an individual (e.g. St Croix et al.
1995). Finally, although the DEF system also incorporates
safety features consisting of monitors for heart rate, pulse
oximetry, inspired O2 concentration, and the presence of
a back-up O2 source, maintaining safety is challenging
because a failure of the O2 flow provides a totally anoxic
inspiratory gas flow that must be detected and rectified
immediately to prevent harm.
Prospective end-tidal targeting. Approximately 15 years
ago, our laboratory set out to develop an automated
device that would reliably administer a repeatable change
in Pa,CO2 , while maintaining isoxia, with minimal sub-
ject cooperation. As BOLD MRI signal was the intended
surrogate for CBF, the equipment needed to be MRI
compatible and compact. It also had to be economical,
and inherently safe. The method that emerged became
known as prospective targeting of PET,CO2 and PET,O2
(Slessarev et al. 2007; Blockley et al. 2011; Alderliesten et al.
2013). The core feature of the method is the capability of
controlling the amount and content of gas entering the
lung gas exchange region independent of the tidal volume
and pattern of breathing. This capability was achieved by
using a simple 3-valve manifold and circuit that, with
control of the flow of gas to the circuit, produced a
sequential delivery of inspired and previously exhaled gas.
Its operation is illustrated in Fig. 2.
As Fig. 2 shows, gases from the inspiratory reservoir and
from the expiratory reservoir are delivered sequentially
Figure 2. The sequential gas delivery circuit (SGD) operation
The valve manifold has an inspiratory valve (1), an expiratory valve
(2) and a cross-over valve (3). The latter has a slightly greater
opening pressure than the other valves and, when open allows gas
to cross from the expiratory to the inspiratory limb. During
expiration, gas delivered by the gas blender enters the inspiratory
gas reservoir (green dotted line), and exhaled gas enters the expired
gas reservoir (blue dashed line).During inspiration, gas is drawn from
the stored blender gas in the inspiratory gas reservoir (green dotted
lines). If the inspired volume exceeds the volume in the inspiratory
reservoir, the balance comes from the expiratory gas reservoir via the
cross-over valve (blue dashed line).
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during inspiration (Sommer et al. 1998; Somogyi et al.
2005; Slessarev et al. 2007). The functional significance
of this arrangement is that the rebreathed gas in the
expiratory reservoir, having already equilibrated with the
blood, provides no gradient for any further gas exchange,
i.e. rebreathed gas is neutral with respect to pulmonary
gas exchange. This sequential gas delivery (SGD) means
that the gas supplied to the inspiratory reservoir is the
only source of gas available for gas exchange in the lung.
Provided the subject empties the inspiratory reservoir for
each breath, the output of the gas blender is the alveolar
ventilation, regardless of actual breath size or breathing
pattern.
This prospective targeting methodology confers four
major advantages. First, with alveolar ventilation pre-
cisely administered by the gas blender, gas tensions can
be accurately targeted because PET,CO2 and PET,O2 are
determined by the gas fractional concentrations in the
alveolar ventilation (Slessarev et al. 2007). Moreover,
the targeting of each gas is independent of the other
as well as independent of both the minute ventilation
and the breathing pattern of the subject, as Fig. 3
illustrates. Second, gas blender flows to the SGD circuit
approximate resting ventilation, so that more compact
gas sources can be used, and gas utilization is minimized
and expenses reduced. Also the system operation is quiet,
and gas humidification can easily be achieved. Third,
the prospective nature of the system targeting eliminates
the need for a feedback correction mechanism thereby
markedly reducing the computational complexity while
minimizing the breath-to-breath variability of PET,CO2 .
Fourth, a minimal degree of cooperation is required of
the subjects; all they need to do is breathe so that their
ventilation exceeds the blender gas flow to the inspiratory
reservoir. Finally, and most important, because the SGD
circuit includes an element of expired gas rebreathing,
alveolar inhomogeneities are reduced and, as a result, the
gradient between PET,CO2 and Pa,CO2 is reduced to the
range of instrument measuring error (0.5± 1.7 mmHg;
P = 0.53; Ito et al. 2008; Fierstra et al. 2011) under steady
conditions.
Until now it has not been possible to accurately specify
the Pa,CO2 stimulus, and so it was not known how
precisely the BOLD MRI signal follows the change in
Pa,CO2 . We found that after synchronizing the phases
of the PET,CO2 and BOLD signals, the waveforms track
precisely, voxel-by-voxel as shown in Fig. 4. This
observation demonstrates that any inaccuracies of the
Figure 3. Examples of PET,CO2 and PET,O2 control in a subject using an SGD breathing circuit and
prospective end-tidal targeting
The continuous traces from sampling at the mask are PCO2 (blue upper) and PO2 (red lower). End-tidal values
are PET,CO2 (red filled squares) and PET,O2 (green filled circles), each representing a single breath. A, sinusoidal
changes of PET,CO2 and PET,O2 are implemented in phase until the blue arrow, when the phase of the PET,O2 is
changed 180 deg. B, sinusoidal changes of PET,CO2 and PET,O2 are implemented with the period of PET,O2 twice
that of PET,CO2 . C, simultaneous square wave changes in PET,CO2 and PET,O2 are implemented independently of
each other. In the sinusoidal patterns, the target PET,CO2 and PET,O2 change with each breath. The algorithm
used to reach these targets is context sensitive, that is, it takes into account the current gas concentrations in the
lung as well as the target history. This means that the set of flows and inspired gas concentrations differ – even
for the same recurrent end-tidal target values, whether they be in a sinusoidal sequence or steady target level.
The algorithm uses the baseline PCO2 , and resting CO2 production and O2 consumption to calculate inspired gas
parameters. Baseline PCO2 is based on the PET,CO2 during rest. Resting CO2 production and O2 consumption are
calculated from a nomogram based on sex, height and weight. Errors in presumption of CO2 production or O2
consumption, or changes in these due to changes in activity or muscle tone, result in target values drifting over
time, as can be seen in A and C.
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independent variable Pa,CO2 will result in inaccuracies of
the CVR measurements, and so impede interpretation.
The computer controlled gas blender and SGD circuit can
be used to prospectively target Pa,CO2 , which is accurately
andprecisely knownat breath-by-breath intervals through
the measurement of PET,CO2 .
However, as well as the advantages described above, the
prospective targeting system, has a number of limitations
associated with its application. As discussed in the caption
in Fig. 3, initialization of the targeting software requires
unmeasured parameters such as baseline Pa,CO2 , CO2
production and O2 consumption; incorrect assumptions
are a source of error in targeting. In addition, the
achievement of precise targeting has fastidious technical
requirements; the most important of which is that the
interface with the subject be absolutely airtight. Skin
tape such as Tegaderm (3M, St Paul MN, USA) is used
around the mask by most investigators. Although the
breathing circuit is simple in design, it nevertheless
has strict performance requirements, particularly in
the competence of the valves and the condition of
the reservoirs during targeting (e.g. collapse of the
inspiratory reservoir on inspiration; venting the expiratory
reservoir without contaminating its contents with air).
The system requires preparation of two custom blend
gases containing different concentrations of O2, CO2
and N2 to circumvent the possibility of administering
hypoxic gas. Subjects must cooperate to the extent that
they empty the inspiratory reservoir each breath so that,
on occasion, they must either increase their minute
ventilation on command; alternatively, the user can reduce
the blend gas flow (whereby the gas concentrations
automatically adjust to maintain targeting). Thus, the
gas blender and associated software, like that of DEF
system, are too complex for most laboratories to assemble
and achieve sophistication and safety. Neither are they
currently regulatory approved commercially available
devices. Nevertheless, we have made every effort to
selectively make available hand-assembled devices for
collaborative research, resulting in about 60 publications
in the peer reviewed literature enabled by the device.
Conclusions
Measures of CBF are now highly reproducible, but
variability of the vasoactive stimulus remains a
major impediment in the pursuit of a standardized
cerebrovascular test employing CVR measurement.
Reducing this source of variability will further advance
the art towards the goal of generating useful comparisons
of CVR maps between subjects or groups of subjects,
as well as the ability to follow CVR changes in a given
subject over time. After reviewing the various vasoactive
stimuli, we conclude that while the modified rebreathing
method may be used to measure CVR with TCD, only
the computer controlled gas delivery DEF and prospective
end-tidal gas targeting systems are capable of providing
reliable and repeatable vasoactive CO2 stimuli for both
TCD and clinically available imaging techniques such
as BOLD MRI that produce CVR maps. These latter
methods, therefore, may be candidates for incorporation
into standardized CVR measurements; of these systems,
prospective end-tidal targeting is the most practical for
routine testing (Spano et al. 2012) with all measurement
modalities.
Figure 4. Voxel tracking of PET,CO2
CVR maps, constructed as for Fig. 1, are shown
on the left with chosen voxels indicated by the
cross-hairs. The right side shows graphs of the
time course of the chosen voxels BOLD signals
(blue dots) in response to the changes in
PET,CO2 (red dots). A, a voxel with positive CVR.
B, a voxel with negative CVR (vascular steal). In
each case the BOLD signals track the PET,CO2
stimulus, indicating that a precise and accurate
measurement of CVR requires accuracy and
precision of the Pa,CO2 stimulus as well as the
surrogate measure of cerebral blood flow.
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Appendix
A selective primer in respiratory physiology
Terminology
Alveolar ventilation The gas in the lungs contributing to
gas exchange with the blood
Breath hold index PCO2 increase divided by breath-hold
time
CO2 Carbon dioxide
FCO2 Fractional concentration of CO2, the
proportion of CO2 in a gas
Hypercapnia Higher than normal PCO2
Hypocapnia Lower than normal PCO2
Minute ventilation Gas volume exchanged in the lungs in
litres per minute
PCO2 Partial pressure of CO2
Peak inspiratory flow Peak flow of gas during a breath
PET,CO2 End-tidal partial pressure of carbon
dioxide
Rebreathing Inhaling previously exhaled gas
Ventilatory drive The urge to breathe
Carbon dioxide (CO2) is produced in the body by
metabolism, so thatCO2 levels in theblood aredetermined
by thebalancebetween the rate of productionby the tissues
and the rate of elimination through the lungs.
The partial pressure of CO2(PCO2), in a gas mixture
is FCO2 times the ambient pressure (Henry’s law). Partial
pressure determines themovement of gases in the body, so
the concentration of CO2 in the blood is a function of PCO2
(CO2 dissociation curve). The partial pressure of CO2 in
arterial blood is represented as Pa,CO2 , which is considered
to be the independent variable affecting the flow resistance
of cerebral vessels.
End-tidal PCO2 (PET,CO2) is the partial pressure of CO2
in the gas at the end of an exhalation. It is that which has
fully equilibrated with the blood and so is of interest.
Breath-holding (holding one’s breath) reduces the rate
of elimination of CO2 to zero. As a result CO2 accumulates
in the blood and its fractional concentration and partial
pressure rises.
Rebreathing is the inhalation of previously exhaled gas.
As this gas has already equilibrated with the blood, it does
not participate in gas exchange. Therefore the rebreathed
portion of the breath does not contribute to alveolar
ventilation. If the entire breath consists of previously
exhaled gas, the result is the same as breath-holding:
there is a steady accumulation of CO2 in the blood.
The rate of rise of CO2 in the blood depends on the
body’s CO2 production and the body size. There is also
a steady consumption of oxygen (O2), and without O2
replacement, the O2 concentration in the blood falls
continuously. Rebreathing methods therefore require the
addition of O2 to maintain blood O2 levels.
Inhaling CO2 also adds to the accumulation of CO2
in the blood. When the inspired gas has a constant
concentration of CO2, the CO2 level in the blood is
a function of both this inspired concentration (which
tends to raise the concentration of CO2) and the level
of ventilation (which tends to lower it). Since the level of
ventilation to a given inspired concentration of CO2 varies
between people, the blood concentration of CO2 to a given
inspired concentration will vary.
Chemoreflexes control the partial pressure of CO2 in
the blood. If the PCO2 exceeds a threshold the central
and peripheral chemoreflexes effect a reflex increase in
ventilation to restore resting PCO2 .
The relationship between PET,CO2 and Pa,O2 is not
constant. In some healthy people they may be closely
related, but the relationship is not reliable. The only
exception iswhenCO2 is inhaled at the endof abreath.Our
system of prospective targeting of PET,CO2 includes some
rebreathing at the endof inhalation,whichhas been shown
to equalize the PET,CO2 and Pa,CO2 . In this case, the PET,CO2
is an accurate surrogate for the Pa,CO2 , the independent
variable affecting cerebral blood flow.
Tidal volume is the volume of a breath. To generate a
breath thediaphragmandchestmuscles contract. Theflow
of gas into the lungs starts from 0, reaches amaximumand
ends at 0 flow just before exhalation. The maximum flow
at rest in adults can be 50 l min−1. It can be 2 to 3 times this
with greater breathing efforts. When the subject breathes
gas provided by amask that is open to atmosphere (such as
a regular oxygenmask), and the flowof gas does not exceed
this peak inspiratory flow, gas from the room is drawn
into the mask and dilutes the administered gas. Typical
maximum oxygen flows into the mask are 5–15 l min−1.
Maximum flow that can be conducted in standard oxygen
tubing is about 25 l min−1. Meeting peak inspiratory flow
rates requires gas flows of 70 l min−1 or more.
Controlling lung gas concentrations is difficult. After
an exhalation there is a large volume of gas left in
the lung called the ‘functional residual capacity’, or
FRC. The FRC is typically very large (∼3 l in an
adult) compared to the breath size (∼0.5 l). As a result
it takes many breaths to ‘wash out’ the current gas
concentration in the FRCand replace it with gas of another
concentration. Computerized gas delivery systems have
developed strategies to optimize this exchange.
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